UK Markets closed

Moderna, Inc. (MRNA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
165.60-5.46 (-3.19%)
As of 01:47PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close171.06
Bid165.66 x 900
Ask165.74 x 3100
Day's range165.10 - 170.39
52-week range115.03 - 217.25
Avg. volume4,976,447
Market cap63.618B
Beta (5Y monthly)1.69
PE ratio (TTM)N/A
EPS (TTM)-1.96
Earnings date22 Feb 2023 - 27 Feb 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est207.29
  • Zacks

    Moderna (MRNA) Gains But Lags Market: What You Should Know

    Moderna (MRNA) closed the most recent trading day at $171.06, moving +0.46% from the previous trading session.

  • Reuters

    Drug companies face COVID cliff in 2023 as sales set to plummet

    Pharmaceutical companies that made billions from the pandemic over the past two years selling vaccines and treatments are now up against a steep COVID cliff and investor pressure to spend their windfalls wisely. Western drugmakers including Pfizer Inc, BioNTech SE, Moderna Inc, Gilead Sciences Inc, AstraZeneca Plc and Merck & Co are estimated to have brought in about $100 billion in revenue from COVID vaccines and treatments in 2022. Company and analyst estimates suggest those sales could fall by nearly two-thirds this year due to built up product inventories around the world including in the countries that pay the most.

  • Motley Fool

    3 No-Brainer Growth Stocks to Buy in 2023

    In last-year's difficult market, growth stocks were among the first to suffer. Why should we be confident about growth stocks? Moderna (NASDAQ: MRNA) went from zero product revenue prior to the pandemic to about $18 billion annually over the past two years.